Winfried Brenner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Winfried Brenner has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Cheryl Vernon
Division of Nuclear Medicine, University of Washington Medical Center, Seattle, USA
3 shared publicationsEberhard Henze
3 shared publicationsErnest U. Conrad
Department of Orthopedics, University of Washington Medical Center, Seattle, USA
3 shared publicationsJanet F. Eary
Division of Nuclear Medicine, University of Washington Medical Center, Seattle, USA
3 shared publicationsMaaz Zuhayra
3 shared publicationsCorinna Brümmer
Clinic of Nuclear Medicine, Christian-Albrechts-University, Kiel, Germany
2 shared publications
Latest Publications
- 11 July 2006
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 33 (11) , 1290-1295
Risk assessment in liposarcoma patients based on FDG PET imaging
Purpose Tumor grade and subtype are considered standard parameters for risk assessment in patients with liposarcoma. The aim of this study was to assess the clinical value of [18F]fluorodeoxyglucose (FDG) PET-derived maximum standardized uptake value (SUVmax) for prediction of outcome in liposarcoma patients. Methods 18F-FDG PET was performed in 54 patients with liposarcoma prior to therapy. SUVmax was calculated for each tumor and results were correlated with tumor grade, subtype, and relapse-free survival. Results SUVmax ranged from 0.4 to 15.9 (mean 3.6) and was significantly lower in grade I than in grade II and grade III tumors. SUVmax was 2.3±1.7, 3.5±1.5, 4.8±2.5, and 5.6±5.8 in well-differentiated, myxoid/round cell, dedifferentiated, and pleomorphic subtypes, respectively. Borderline differences (p=0.059) were found between tumor SUVmax in patients with and without relapse. Using a SUV of 3.6 as cut-off, the accuracy in predicting a relapse was 75%. Tumor grade yielded a lower accuracy for predicting relapse (50%), as did tumor subtype (35%). In Kaplan-Meier survival analysis, patients with a SUVmax >3.6 had a significantly shorter disease-free survival of 21 months compared with 44 months in patients with a SUVmax ≤3.6. Tumor grading and tumor subtype did not yield significant differences. Conclusion Pretherapy tumor SUV obtained by FDG PET imaging was a more useful parameter for risk assessment in liposarcoma than tumor grade or subtype. A SUVmax of more than 3.6 resulted in a significantly reduced disease-free survival and identified patients at high risk for developing early local recurrences or metastatic disease.
- 11 July 2006
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 33 (11) , 1290-1295
Risk assessment in liposarcoma patients based on FDG PET imaging
Purpose Tumor grade and subtype are considered standard parameters for risk assessment in patients with liposarcoma. The aim of this study was to assess the clinical value of [18F]fluorodeoxyglucose (FDG) PET-derived maximum standardized uptake value (SUVmax) for prediction of outcome in liposarcoma patients. Methods 18F-FDG PET was performed in 54 patients with liposarcoma prior to therapy. SUVmax was calculated for each tumor and results were correlated with tumor grade, subtype, and relapse-free survival. Results SUVmax ranged from 0.4 to 15.9 (mean 3.6) and was significantly lower in grade I than in grade II and grade III tumors. SUVmax was 2.3±1.7, 3.5±1.5, 4.8±2.5, and 5.6±5.8 in well-differentiated, myxoid/round cell, dedifferentiated, and pleomorphic subtypes, respectively. Borderline differences (p=0.059) were found between tumor SUVmax in patients with and without relapse. Using a SUV of 3.6 as cut-off, the accuracy in predicting a relapse was 75%. Tumor grade yielded a lower accuracy for predicting relapse (50%), as did tumor subtype (35%). In Kaplan-Meier survival analysis, patients with a SUVmax >3.6 had a significantly shorter disease-free survival of 21 months compared with 44 months in patients with a SUVmax ≤3.6. Tumor grading and tumor subtype did not yield significant differences. Conclusion Pretherapy tumor SUV obtained by FDG PET imaging was a more useful parameter for risk assessment in liposarcoma than tumor grade or subtype. A SUVmax of more than 3.6 resulted in a significantly reduced disease-free survival and identified patients at high risk for developing early local recurrences or metastatic disease.
- 11 January 2006
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 33 (4) , 428-432
Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours
Purpose In patients with neurofibromatosis type-1 (NF1) and malignant peripheral nerve sheath tumours (MPNSTs), survival rates are low and time to death is often less than 2 years. However, there are patients with a more favourable prognosis who develop metastases rather late or not at all. Since histopathology and tumour grading are not well correlated with prognosis, we aimed to evaluate the potential of 18F-fluorodeoxyglucose positron emission tomography (FDG PET) for prediction of patient outcome in MPNST. Methods FDG PET was performed in 16 patients with NF1 and MPNSTs. Standardised uptake values (SUVs) were calculated for each tumour and correlated to tumour grade and patient outcome in terms of survival or death. Results Three patients with tumour grade II had an SUV 3. Only one of these patients is still alive after 20 months; the remaining 12 died within 4–33 months. SUV predicted long-term survival with an accuracy of 94%, compared with 69% for tumour grade. In Kaplan-Meier survival analysis, patients with an SUV >3 had a significantly shorter mean survival time, 13 months, than patients with an SUV <3, in whom the mean survival time was 52 months. Tumour grading did not reveal differences in survival time (15 vs 12 months). Conclusion Tumour SUV obtained by FDG PET was a significant parameter for prediction of survival in NF1 patients with MPNSTs while histopathological tumour grading did not predict outcome.
- 11 January 2006
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 33 (4) , 428-432
Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours
Purpose In patients with neurofibromatosis type-1 (NF1) and malignant peripheral nerve sheath tumours (MPNSTs), survival rates are low and time to death is often less than 2 years. However, there are patients with a more favourable prognosis who develop metastases rather late or not at all. Since histopathology and tumour grading are not well correlated with prognosis, we aimed to evaluate the potential of 18F-fluorodeoxyglucose positron emission tomography (FDG PET) for prediction of patient outcome in MPNST. Methods FDG PET was performed in 16 patients with NF1 and MPNSTs. Standardised uptake values (SUVs) were calculated for each tumour and correlated to tumour grade and patient outcome in terms of survival or death. Results Three patients with tumour grade II had an SUV 3. Only one of these patients is still alive after 20 months; the remaining 12 died within 4–33 months. SUV predicted long-term survival with an accuracy of 94%, compared with 69% for tumour grade. In Kaplan-Meier survival analysis, patients with an SUV >3 had a significantly shorter mean survival time, 13 months, than patients with an SUV <3, in whom the mean survival time was 52 months. Tumour grading did not reveal differences in survival time (15 vs 12 months). Conclusion Tumour SUV obtained by FDG PET was a significant parameter for prediction of survival in NF1 patients with MPNSTs while histopathological tumour grading did not predict outcome.
- 1 September 2004
- Vol. 45 (9) , 1493-500
Comparison of different quantitative approaches to 18F-fluoride PET scans.
The aim of this study was to evaluate the relationship between 18F-fluoride bone metabolic measures obtained by nonlinear regression (NLR), Patlak analysis, and standardized uptake value (SUV) for a wide range of normal and pathologic bone conditions. In patients imaged twice, changes in metabolic rates were determined using the different quantitation methods. In 33 patients 2-51 mo after resection of a bone tumor of the limbs, a total of 42 dynamic PET scans were performed after injection of 250-350 MBq 18F-fluoride. SUV, fluoride bone influx rate obtained by Patlak analysis (KPat), and fluoride bone influx rate obtained by NLR (KNLR) were calculated in each patient for the bone graft, the contralateral normal side, and the spine, if within the field of view. SUV ranged from 0.4 to 9.9, KPat from 0.0035 to 0.0742 mL/min/mL, and KNLR from 0.0027 to 0.0737 mL/min/mL. Significant linear correlations were found between KPat and KNLR (r = 0.99), KPat and SUV (r = 0.95), and KNLR and SUV (r = 0.93). Eight patients have been imaged twice within 6 mo. Changes in metabolic values of the grafts were significantly correlated for KPat and KNLR (r = 0.96), KPat and SUV (r = 0.88), and KNLR and SUV (r = 0.79). The 95% ranges of normal change in limb bones were +/-58.0% for SUV, +/-23.0% for KPat, and +/-20.2% for KNLR; the corresponding 95% ranges in the spine were +/-8.6%, +/-7.6%, and +/-19.6%. The results of this study show that 18F-fluoride metabolic values as well as changes in bone metabolism measured by SUV and Patlak analysis were strongly correlated with NLR findings. The high 95% range of normal change of SUV in limb bones, however, indicates that this parameter is of limited value in areas with low metabolic activity. The range of spontaneous bone metabolic rate fluctuations presented in this study may be used as an estimate for assessing changes in bone metabolic activity, and the normal values for limb bones provide a basis for further studies on 18F-fluoride bone metabolism.
- 1 September 2004
- Vol. 45 (9) , 1493-500
Comparison of different quantitative approaches to 18F-fluoride PET scans.
The aim of this study was to evaluate the relationship between 18F-fluoride bone metabolic measures obtained by nonlinear regression (NLR), Patlak analysis, and standardized uptake value (SUV) for a wide range of normal and pathologic bone conditions. In patients imaged twice, changes in metabolic rates were determined using the different quantitation methods. In 33 patients 2-51 mo after resection of a bone tumor of the limbs, a total of 42 dynamic PET scans were performed after injection of 250-350 MBq 18F-fluoride. SUV, fluoride bone influx rate obtained by Patlak analysis (KPat), and fluoride bone influx rate obtained by NLR (KNLR) were calculated in each patient for the bone graft, the contralateral normal side, and the spine, if within the field of view. SUV ranged from 0.4 to 9.9, KPat from 0.0035 to 0.0742 mL/min/mL, and KNLR from 0.0027 to 0.0737 mL/min/mL. Significant linear correlations were found between KPat and KNLR (r = 0.99), KPat and SUV (r = 0.95), and KNLR and SUV (r = 0.93). Eight patients have been imaged twice within 6 mo. Changes in metabolic values of the grafts were significantly correlated for KPat and KNLR (r = 0.96), KPat and SUV (r = 0.88), and KNLR and SUV (r = 0.79). The 95% ranges of normal change in limb bones were +/-58.0% for SUV, +/-23.0% for KPat, and +/-20.2% for KNLR; the corresponding 95% ranges in the spine were +/-8.6%, +/-7.6%, and +/-19.6%. The results of this study show that 18F-fluoride metabolic values as well as changes in bone metabolism measured by SUV and Patlak analysis were strongly correlated with NLR findings. The high 95% range of normal change of SUV in limb bones, however, indicates that this parameter is of limited value in areas with low metabolic activity. The range of spontaneous bone metabolic rate fluctuations presented in this study may be used as an estimate for assessing changes in bone metabolic activity, and the normal values for limb bones provide a basis for further studies on 18F-fluoride bone metabolism.
- 10 June 2004
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 31 (9) , 1291-1298
Assessment of the metabolic activity of bone grafts with 18F-fluoride PET
The aims of this prospective study were to evaluate quantitative approaches to 18F-fluoride positron emission tomography (PET) imaging in allogenic bone grafts of the limbs, and to assess the time course of graft healing after surgery. We performed a total of 52 dynamic 18F-fluoride PET studies in 34 patients with cancellous and full bone grafts. Seven patients were imaged three times at 6, 12, and 24 months after surgery, and four patients were imaged twice. PET data were quantitatively analyzed using non-linear regression (NLR) analysis, Patlak analysis, and standardized uptake value (SUV). Fluoride bone metabolism in cancellous grafts decreased by 25% from 6 to 12 months post surgery, and revealed a total decrease of 60–65% after 2 years for SUV, K Pat, and K NLR. Full bone grafts first showed an increase by 20% from 6 to 12 months and from then on decreased to 70% of the initial activity at the end of 2 years with either quantification method. In two patients with non-union of their full bone grafts, increases in SUV, K Pat, K NLR, and K 1 far above average and outside the normal time pattern were observed. Highly significant correlations were found between SUV, K Pat, K NLR, and K 1 for both grafts and normal limb bones. In patients imaged repeatedly, the percentage changes in fluoride graft metabolism were also significantly correlated between SUV, K Pat, and K NLR. Quantitative 18F-fluoride PET is a promising tool for assessment of fluoride metabolism and normal healing in bone grafts of the limbs.
- 10 June 2004
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 31 (9) , 1291-1298
Assessment of the metabolic activity of bone grafts with 18F-fluoride PET
The aims of this prospective study were to evaluate quantitative approaches to 18F-fluoride positron emission tomography (PET) imaging in allogenic bone grafts of the limbs, and to assess the time course of graft healing after surgery. We performed a total of 52 dynamic 18F-fluoride PET studies in 34 patients with cancellous and full bone grafts. Seven patients were imaged three times at 6, 12, and 24 months after surgery, and four patients were imaged twice. PET data were quantitatively analyzed using non-linear regression (NLR) analysis, Patlak analysis, and standardized uptake value (SUV). Fluoride bone metabolism in cancellous grafts decreased by 25% from 6 to 12 months post surgery, and revealed a total decrease of 60–65% after 2 years for SUV, K Pat, and K NLR. Full bone grafts first showed an increase by 20% from 6 to 12 months and from then on decreased to 70% of the initial activity at the end of 2 years with either quantification method. In two patients with non-union of their full bone grafts, increases in SUV, K Pat, K NLR, and K 1 far above average and outside the normal time pattern were observed. Highly significant correlations were found between SUV, K Pat, K NLR, and K 1 for both grafts and normal limb bones. In patients imaged repeatedly, the percentage changes in fluoride graft metabolism were also significantly correlated between SUV, K Pat, and K NLR. Quantitative 18F-fluoride PET is a promising tool for assessment of fluoride metabolism and normal healing in bone grafts of the limbs.
- 1 March 2004
- Vol. 45 (3) , 512-8
111In-labeled CD34+ hematopoietic progenitor cells in a rat myocardial infarction model.
Transplantation of progenitor cells (PCs) has been shown to improve neovascularization and left ventricular function after myocardial ischemia. The fate of transplanted PCs has been monitored by fluorescence labeling or by genetic modifications introducing reporter genes. However, these techniques are limited by the need to kill the experimental animal. The aim of this study was to radiolabel CD34(+) hematopoietic PCs (HPCs) with (111)In-oxine and to evaluate the feasibility of this in vivo method for monitoring myocardial homing of transplanted cells in a rat myocardial infarction model. Human HPCs were isolated from mobilized peripheral blood and labeled with (111)In-oxine. Labeled HPCs were injected into the cavity of the left ventricle in nude rats 24 h after induction of myocardial infarction (n = 4) or sham operation (n = 4). Scintigraphic images were acquired up to 96 h after HPC injection. After animals were killed, tissue samples of various organs were harvested to calculate tissue-specific activity and for immunostaining. Labeling efficiency of HPCs was 32% +/- 11%. According to trypan-blue staining, viability of radiolabeled HPCs was impaired by 30% after 48 and 96 h in comparison with unlabeled cells, whereas proliferation and differentiation of HPCs was nullified after 7 d, as assessed by colony-forming assays. After injection of HPCs, the specific activity ratio of heart to peripheral muscle tissue increased from 1.10 +/- 0.32 in sham-operated rats to 2.47 +/- 0.92 (P = 0.020) in infarcted rats. However, the overall radioactivity detected in the heart was only about 1%. A transient high lung uptake of 17% +/- 6% was observed within the first hour after infusion of HPCs. At 24 h after injection, the initial lung activity had shifted toward liver, kidneys, and spleen, resulting in an increase of radioactivity in these organs from 37% +/- 6% to 57% +/- 5%. Radiolabeling with (111)In-oxine is a feasible in vivo method for monitoring transplanted HPCs in a rat myocardial infarction model. The potential to detect differences in myocardial homing between infarcted and normal hearts suggests that this method may provide a noninvasive imaging approach for clinical trials using transplanted HPCs in patients. Our findings, however, also demonstrated a negative effect of (111)In-oxine on cellular function, which resulted in complete impairment of HPC proliferation and differentiation. For future trials in stem cell imaging with (111)In-oxine, therefore, it will be mandatory to carefully check for radiation-induced cell damage.
- 1 March 2004
- Vol. 45 (3) , 512-8
111In-labeled CD34+ hematopoietic progenitor cells in a rat myocardial infarction model.
Transplantation of progenitor cells (PCs) has been shown to improve neovascularization and left ventricular function after myocardial ischemia. The fate of transplanted PCs has been monitored by fluorescence labeling or by genetic modifications introducing reporter genes. However, these techniques are limited by the need to kill the experimental animal. The aim of this study was to radiolabel CD34(+) hematopoietic PCs (HPCs) with (111)In-oxine and to evaluate the feasibility of this in vivo method for monitoring myocardial homing of transplanted cells in a rat myocardial infarction model. Human HPCs were isolated from mobilized peripheral blood and labeled with (111)In-oxine. Labeled HPCs were injected into the cavity of the left ventricle in nude rats 24 h after induction of myocardial infarction (n = 4) or sham operation (n = 4). Scintigraphic images were acquired up to 96 h after HPC injection. After animals were killed, tissue samples of various organs were harvested to calculate tissue-specific activity and for immunostaining. Labeling efficiency of HPCs was 32% +/- 11%. According to trypan-blue staining, viability of radiolabeled HPCs was impaired by 30% after 48 and 96 h in comparison with unlabeled cells, whereas proliferation and differentiation of HPCs was nullified after 7 d, as assessed by colony-forming assays. After injection of HPCs, the specific activity ratio of heart to peripheral muscle tissue increased from 1.10 +/- 0.32 in sham-operated rats to 2.47 +/- 0.92 (P = 0.020) in infarcted rats. However, the overall radioactivity detected in the heart was only about 1%. A transient high lung uptake of 17% +/- 6% was observed within the first hour after infusion of HPCs. At 24 h after injection, the initial lung activity had shifted toward liver, kidneys, and spleen, resulting in an increase of radioactivity in these organs from 37% +/- 6% to 57% +/- 5%. Radiolabeling with (111)In-oxine is a feasible in vivo method for monitoring transplanted HPCs in a rat myocardial infarction model. The potential to detect differences in myocardial homing between infarcted and normal hearts suggests that this method may provide a noninvasive imaging approach for clinical trials using transplanted HPCs in patients. Our findings, however, also demonstrated a negative effect of (111)In-oxine on cellular function, which resulted in complete impairment of HPC proliferation and differentiation. For future trials in stem cell imaging with (111)In-oxine, therefore, it will be mandatory to carefully check for radiation-induced cell damage.
- 1 February 2004
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 31 (2) , 189-195
FDG PET imaging for grading and prediction of outcome in chondrosarcoma patients
The aims of this study were to assess the potential of fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) for tumor grading in chondrosarcoma patients and to evaluate the role of standardized uptake value (SUV) as a parameter for prediction of patient outcome. FDG PET imaging was performed in 31 patients with chondrosarcoma prior to therapy. SUV was calculated for each tumor and correlated to tumor grade and size, and to patient outcome in terms of local relapse or metastatic disease with a mean follow-up period of 48 months. Chondrosarcomas were detectable in all patients. Tumor SUV was 3.38±1.61 for grade I (n=15), 5.44±3.06 for grade II (n=13), and 7.10±2.61 for grade III (n=3). Significant differences were found between patients with and without disease progression: SUV was 6.42±2.70 (n=10) in patients developing recurrent or metastatic disease compared with 3.74±2.22 in patients without relapse (P=0.015). Using a cut-off of 4 for SUV, sensitivity, specificity, and positive and negative predictive values for a relapse were 90%, 76%, 64%, and 94%, respectively. Combining tumor grade and SUV, these parameters improved to 90%, 95%, 90%, and 95%, respectively. Pretherapeutic tumor SUV obtained by FDG PET imaging was a useful parameter for tumor grading and prediction of outcome in chondrosarcoma patients. The combination of SUV and histopathologic tumor grade further improved prediction of outcome substantially, allowing identification of patients at high risk for local relapse or metastatic disease.
- 1 February 2004
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 31 (2) , 189-195
FDG PET imaging for grading and prediction of outcome in chondrosarcoma patients
The aims of this study were to assess the potential of fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) for tumor grading in chondrosarcoma patients and to evaluate the role of standardized uptake value (SUV) as a parameter for prediction of patient outcome. FDG PET imaging was performed in 31 patients with chondrosarcoma prior to therapy. SUV was calculated for each tumor and correlated to tumor grade and size, and to patient outcome in terms of local relapse or metastatic disease with a mean follow-up period of 48 months. Chondrosarcomas were detectable in all patients. Tumor SUV was 3.38±1.61 for grade I (n=15), 5.44±3.06 for grade II (n=13), and 7.10±2.61 for grade III (n=3). Significant differences were found between patients with and without disease progression: SUV was 6.42±2.70 (n=10) in patients developing recurrent or metastatic disease compared with 3.74±2.22 in patients without relapse (P=0.015). Using a cut-off of 4 for SUV, sensitivity, specificity, and positive and negative predictive values for a relapse were 90%, 76%, 64%, and 94%, respectively. Combining tumor grade and SUV, these parameters improved to 90%, 95%, 90%, and 95%, respectively. Pretherapeutic tumor SUV obtained by FDG PET imaging was a useful parameter for tumor grading and prediction of outcome in chondrosarcoma patients. The combination of SUV and histopathologic tumor grade further improved prediction of outcome substantially, allowing identification of patients at high risk for local relapse or metastatic disease.
- 1 December 2003
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 18 (6) , 887-893
Myeloprotective Effects of Different Amifostine Regimens in Rabbits Undergoing High-Dose Treatment with 186 Rhenium-(tin)1,1- Hydroxyethylidene Diphosphonate ( 186 Re-HEDP)
The aim of this study is to investigate the myeloprotective effects of different amifostine regimens in rabbits undergoing high-dose treatment with 186Rhenium-(tin)1,1-hydroxyethylidene diphosphonate (186Re-HEDP) and to analyze the impact of amifostine on the bone uptake of the radiopharmaceutical. All animals were treated with 1000 MBq 186Re-HEDP. Group ReA received 500 mg amifostine prior to radionuclide therapy, group ReA3 received 3 × 200 mg amifostine 24 hours and 30 minutes prior to and 24 hours after radionuclide therapy. Group ReC served as control receiving no amifostine. Scintigrams were acquired to quantify the skeletal uptake of 186Re-HEDP, and platelet and leucocyte counts were measured. The mean decrease in platelets was 36% ± 2%, 37% ± 3%, and 61% ± 5% for ReA, ReA3, and ReC, respectively. The decrease in ReC was significantly higher than in amifostine-treated animals with no difference between ReA and ReA3. For the leucocytes the mean decrease was 75% ± 12%, 82% ± 5%, and 73% ± 4%, with no significant differences between the respective groups. Bone uptake of 186Re-HEDP was significantly reduced by 50% in ReA and ReA3 compared to ReC. Thus, the 3-day amifostine regimen had no advantage over the single dose regimen, with both regimens reducing bone uptake and yielding a platelet-protective but no leucoprotective effect.
- 1 December 2003
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 18 (6) , 887-893
Myeloprotective Effects of Different Amifostine Regimens in Rabbits Undergoing High-Dose Treatment with 186 Rhenium-(tin)1,1- Hydroxyethylidene Diphosphonate ( 186 Re-HEDP)
The aim of this study is to investigate the myeloprotective effects of different amifostine regimens in rabbits undergoing high-dose treatment with 186Rhenium-(tin)1,1-hydroxyethylidene diphosphonate (186Re-HEDP) and to analyze the impact of amifostine on the bone uptake of the radiopharmaceutical. All animals were treated with 1000 MBq 186Re-HEDP. Group ReA received 500 mg amifostine prior to radionuclide therapy, group ReA3 received 3 × 200 mg amifostine 24 hours and 30 minutes prior to and 24 hours after radionuclide therapy. Group ReC served as control receiving no amifostine. Scintigrams were acquired to quantify the skeletal uptake of 186Re-HEDP, and platelet and leucocyte counts were measured. The mean decrease in platelets was 36% ± 2%, 37% ± 3%, and 61% ± 5% for ReA, ReA3, and ReC, respectively. The decrease in ReC was significantly higher than in amifostine-treated animals with no difference between ReA and ReA3. For the leucocytes the mean decrease was 75% ± 12%, 82% ± 5%, and 73% ± 4%, with no significant differences between the respective groups. Bone uptake of 186Re-HEDP was significantly reduced by 50% in ReA and ReA3 compared to ReC. Thus, the 3-day amifostine regimen had no advantage over the single dose regimen, with both regimens reducing bone uptake and yielding a platelet-protective but no leucoprotective effect.
- 1 June 2003
- Vol. 44 (6) , 930-42
PET imaging of osteosarcoma.
During the past decade the clinical value of PET imaging has been investigated for many different tumors. As knowledge of the advantages and limitations of this modality increased, PET has gained acceptance in tumor imaging. (18)F-FDG PET is now successfully used and approved for procedure reimbursement in many types of cancer-for example, lung cancer, melanoma, lymphoma, head and neck tumors, brain tumors, esophageal cancer, and colorectal cancer. In osteosarcoma, the introduction of neoadjuvant chemotherapy has dramatically improved survival rates, thus changing the demands for state-of-the-art imaging to provide detailed information on tumor staging and grading, evaluating treatment, and detecting recurrences. In this review, the available literature on PET imaging in osteosarcoma patients is critically summarized with respect to diagnosis, staging, therapy monitoring, and follow-up focusing on the clinically used tracers (18)F-FDG and (18)F-fluoride ion. Potential and probable indications are outlined. Because of the relatively small number of patients enrolled in clinical trials published to date, further research needs to be done in larger, prospective patient series to determine the full utility of PET in osteosarcoma.
- 1 June 2003
- Vol. 44 (6) , 930-42
PET imaging of osteosarcoma.
During the past decade the clinical value of PET imaging has been investigated for many different tumors. As knowledge of the advantages and limitations of this modality increased, PET has gained acceptance in tumor imaging. (18)F-FDG PET is now successfully used and approved for procedure reimbursement in many types of cancer-for example, lung cancer, melanoma, lymphoma, head and neck tumors, brain tumors, esophageal cancer, and colorectal cancer. In osteosarcoma, the introduction of neoadjuvant chemotherapy has dramatically improved survival rates, thus changing the demands for state-of-the-art imaging to provide detailed information on tumor staging and grading, evaluating treatment, and detecting recurrences. In this review, the available literature on PET imaging in osteosarcoma patients is critically summarized with respect to diagnosis, staging, therapy monitoring, and follow-up focusing on the clinically used tracers (18)F-FDG and (18)F-fluoride ion. Potential and probable indications are outlined. Because of the relatively small number of patients enrolled in clinical trials published to date, further research needs to be done in larger, prospective patient series to determine the full utility of PET in osteosarcoma.
- 1 February 2003
- Vol. 44 (2) , 247-51
Bone uptake studies in rabbits before and after high-dose treatment with 153Sm-EDTMP or 186Re-HEDP.
The aim of this animal study was to measure the bone uptake of (99m)Tc-hydroxymethylene diphosphonate (HDP) before and after high-dose treatment with (153)Sm-ethylenediaminetetramethylenephosphonate (EDTMP) or (186)Re-(tin)1,1-hydroxyethylidene diphosphonate (HEDP) to prove or disprove post-therapeutic alterations of bone uptake of radiolabeled bisphosphonates. Quantitative bone scanning using 100 MBq (99m)Tc-HDP was performed on 12 rabbits before and 8 wk after radionuclide therapy with 1,000 MBq of either (153)Sm-EDTMP or (186)Re-HEDP. Whole-body images were acquired at 3 min, 3 h, and 24 h after injection, and the activities for the whole body, urinary bladder, and soft tissue were measured by region-of-interest technique. From these data, bone uptake was calculated as initial whole-body activity minus urinary excretion and remainder soft-tissue activity. In animals treated with (153)Sm-EDTMP (n = 6), no differences could be proven for the bone uptake of (99m)Tc-HDP at 24 h after injection before and after therapy (51.1% +/- 5.5% vs. 48.0% +/- 6.1%, P > 0.05). There were also no significant differences for the remainder soft-tissue activities and the urinary excretion rates before and after therapy. Similar results were obtained in rabbits treated with (186)Re-HEDP: Bone uptake (44.8% +/- 6.7% vs. 40.4% +/- 4.9%, P > 0.05) and urinary excretion revealed no significant differences before and after treatment. No significant impairment of bone uptake of (99m)Tc-HDP could be observed 8 wk after high-dose radionuclide bone therapy. Because both the biokinetic data obtained for (186)Re-HEDP and (153)Sm-EDTMP and the myelotoxic effects were quite similar in rabbits to those in patients, it seems justifiable to expect the same result (i.e., no significant alteration of bone uptake of radiolabeled bisphosphonates) in patients undergoing a second radionuclide therapy within 2-3 mo after standard treatment with (186)Re-HEDP or (153)Sm-EDTMP.
- 1 February 2003
- Vol. 44 (2) , 247-51
Bone uptake studies in rabbits before and after high-dose treatment with 153Sm-EDTMP or 186Re-HEDP.
The aim of this animal study was to measure the bone uptake of (99m)Tc-hydroxymethylene diphosphonate (HDP) before and after high-dose treatment with (153)Sm-ethylenediaminetetramethylenephosphonate (EDTMP) or (186)Re-(tin)1,1-hydroxyethylidene diphosphonate (HEDP) to prove or disprove post-therapeutic alterations of bone uptake of radiolabeled bisphosphonates. Quantitative bone scanning using 100 MBq (99m)Tc-HDP was performed on 12 rabbits before and 8 wk after radionuclide therapy with 1,000 MBq of either (153)Sm-EDTMP or (186)Re-HEDP. Whole-body images were acquired at 3 min, 3 h, and 24 h after injection, and the activities for the whole body, urinary bladder, and soft tissue were measured by region-of-interest technique. From these data, bone uptake was calculated as initial whole-body activity minus urinary excretion and remainder soft-tissue activity. In animals treated with (153)Sm-EDTMP (n = 6), no differences could be proven for the bone uptake of (99m)Tc-HDP at 24 h after injection before and after therapy (51.1% +/- 5.5% vs. 48.0% +/- 6.1%, P > 0.05). There were also no significant differences for the remainder soft-tissue activities and the urinary excretion rates before and after therapy. Similar results were obtained in rabbits treated with (186)Re-HEDP: Bone uptake (44.8% +/- 6.7% vs. 40.4% +/- 4.9%, P > 0.05) and urinary excretion revealed no significant differences before and after treatment. No significant impairment of bone uptake of (99m)Tc-HDP could be observed 8 wk after high-dose radionuclide bone therapy. Because both the biokinetic data obtained for (186)Re-HEDP and (153)Sm-EDTMP and the myelotoxic effects were quite similar in rabbits to those in patients, it seems justifiable to expect the same result (i.e., no significant alteration of bone uptake of radiolabeled bisphosphonates) in patients undergoing a second radionuclide therapy within 2-3 mo after standard treatment with (186)Re-HEDP or (153)Sm-EDTMP.